There is growing evidence indicating a major influence of changes in the gastrointestinal tract, with its microorganisms, immune cells and barrier function, on many acute and chronic diseases. ImmuneBiotech AB represents new therapeutic strategies aiming at reducing or eliminating causative factors targeting our gut’s mucosal immune system.
Turning knowledge and innovation into action
The company aims to develop, market, and sell innovative products independently, or with partners. As a part of the financing strategies, ImmuneBiotech AB provides contract research and consulting services in the area of pre-clinical development, evaluation of pharmaceutical drug/diagnostic tool effectiveness, and optimizing R&D, based on its long experience of in vivo pre-clinical models for some common human diseases including multiple sclerosis, rheumatoid arthritis, type 1 diabetes mellitus, sepsis, inflammatory bowel diseases (IBD) and cancer. The company promotes a collaborative environment by leveraging its industry and academic associations to ensure accurate, cost-effective and timely solutions with the highest standard of quality.
ImmuneBiotech AB is a team driven by innovative spirit, calculated risk taking, and sense of communal responsibility. Its vision is to achieve international recognition for excellence of research, and to be at the forefront in generating and using new knowledge for creating cost-efficient advancements that have a true impact on health.